STOCK TITAN

Invitae to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SAN FRANCISCO, May 27, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in the following investor conferences:

  • 42nd Annual William Blair Growth Stock Conference - Formal presentation on Tuesday, June 7, 2022, at 8:40 a.m. Central Time in Chicago.
  • 43rd Annual Goldman Sachs Global Healthcare Conference - Fireside chat on Wednesday, June 15, 2022, at 2:40 p.m. Pacific Time in Rancho Palos Verdes, CA.

A live audio webcast of each presentation may be accessed by visiting the investors section of the company website at ir.invitae.com. Replays of the webcasts will be available shortly after the conclusion of each presentation.

About Invitae

Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com.

Contact:
Jack Finks
ir@invitae.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/invitae-to-present-at-upcoming-investor-conferences-301556156.html

SOURCE Invitae Corporation

Invitae Corporation

NYSE:NVTA

NVTA Rankings

NVTA Latest News

NVTA Stock Data

5.59M
284.38M
1.51%
47.96%
23.65%
Medical Laboratories
Health Care and Social Assistance
Link
US
San Francisco

About NVTA

invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people. specializing in genetic diagnostics for hereditary disorders, invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today. choose from our curated panels or design your own test for the same low price. today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. together we can improve healthcare for billions of people.